Product
E6201
2 clinical trials
5 indications
Indication
CancerIndication
Stage IV Cutaneous MelanomaIndication
Brain MetastasesIndication
Metastatic MelanomaClinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2011-08-01
Clinical trial
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-12-01